{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:36:31Z","timestamp":1761561391311},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>OBJETIVO: Avaliar os resultados econ\u00f4micos do seguimento farmacoterap\u00eautico (SFT) em pacientes com diabetes melito tipo 2 em farm\u00e1cias comunit\u00e1rias privadas do sistema suplementar de Sa\u00fade. M\u00c9TODOS: Foi realizado estudo cl\u00ednico prospectivo com 161 pacientes separados em dois grupos, dos quais somente um recebeu SFT durante 12 meses. A partir dos resultados, foram calculados os dados de efetividade e os custos. O desfecho prim\u00e1rio foi a avalia\u00e7\u00e3o econ\u00f4mica do SFT por meio da utiliza\u00e7\u00e3o de um indicador de efetividade (varia\u00e7\u00e3o de hemoglobina glicada), relacionada aos custos do atendimento farmac\u00eautico. Os desfechos secund\u00e1rios foram os valores de press\u00e3o arterial, circunfer\u00eancia abdominal e \u00edndice de massa corporal dos pacientes, que foram utilizados e relacionados a custos do atendimento do farmac\u00eautico. RESULTADOS: Foi observada uma redu\u00e7\u00e3o adicional de 1,3% da HbA1 no grupo que recebeu SFT em compara\u00e7\u00e3o ao grupo controle. Os custos anuais por paciente do grupo SFT relacionados \u00e0 redu\u00e7\u00e3o de 1% nos valores da HbA1 foram de R$ 78,83. Para melhoria no controle dos pacientes diab\u00e9ticos tipo 2, esse recurso pode ser implementado com o investimento anual m\u00e9dio de R$ 456,05 por paciente, utilizando SFT e monitoriza\u00e7\u00e3o com testes de glicemia. CONCLUS\u00d5ES: \u00c9 poss\u00edvel obter redu\u00e7\u00e3o da HbA1 para n\u00edveis desejados por meio da utiliza\u00e7\u00e3o do SFT. Este pode ser considerado um recurso adicional para o alcance do controle metab\u00f3lico, resultando, nesse estudo, em um custo de R$ 76,00 paciente\/ano, para redu\u00e7\u00e3o de 1% nos valores da HbA1.<\/jats:p>","DOI":"10.1590\/s0004-27302009000700006","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T15:23:14Z","timestamp":1259335394000},"page":"825-833","source":"Crossref","is-referenced-by-count":7,"title":["Avalia\u00e7\u00e3o econ\u00f4mica do seguimento farmacoterap\u00eautico em pacientes com diabetes melito tipo 2 em farm\u00e1cias comunit\u00e1rias"],"prefix":"10.1590","volume":"53","author":[{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"first","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}]},{"given":"Paula","family":"Rossignoli","sequence":"additional","affiliation":[{"name":"Universidade Positivo, Brasil"}]},{"given":"Ana Carolina","family":"Melchiors","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}]},{"given":"Rosana","family":"Radominski","sequence":"additional","affiliation":[{"name":"UFPR, Brasil"}]},{"given":"Fernando","family":"Fernandez-Llim\u00f3s","sequence":"additional","affiliation":[{"name":"Universidade de Lisboa, Portugal"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Consenso Brasileiro sobre diabetes: Diagn\u00f3stico e classifica\u00e7\u00e3o do diabetes melito e tratamento do diabetes melito tipo 2","year":"2003"},{"issue":"6865","key":"ref2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet P","year":"2001","journal-title":"Nature."},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1590\/S1020-49892001001100005","article-title":"Campanha nacional de detec\u00e7\u00e3o de casos suspeitos de diabetes mellitus no Brasil: relat\u00f3rio preliminar","volume":"10","author":"Barbosa RB","year":"2001","journal-title":"Rev Panam Salud Publica."},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/diacare.26.3.917","article-title":"Economic costs of diabetes in the US in 2002","volume":"26","author":"Hogan P","year":"2003","journal-title":"Diabetes Care."},{"issue":"2","key":"ref5","first-page":"296","article-title":"Economic consequences of diabetes mellitus in the U. S. in 1997","volume":"21","year":"1998","journal-title":"American Diabetes Association. Diabetes Care."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/j.amjmed.2005.04.012","article-title":"Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus","volume":"118 Suppl 5A","author":"Rubin RR","year":"2005","journal-title":"Am J Med."},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.285.2.182","article-title":"Effect of improved glycemic control on health care costs and utilization","volume":"285","author":"Wagner EH","year":"2001","journal-title":"JAMA."},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1331\/108658003321480713","article-title":"The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program","volume":"43","author":"Cranor CW","year":"2003","journal-title":"J Am Pharm Assoc (Wash)."},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/diacare.23.3.390","article-title":"An economic analysis of interventions for diabetes","volume":"23","author":"Klonoff D","year":"2000","journal-title":"Diabetes Care."},{"issue":"1","key":"ref10","first-page":"52","article-title":"La Atenci\u00f3n Farmac\u00e9utica en farmacia comunitaria: evoluci\u00f3n de conceptos, necesidades de formaci\u00f3n, modalidades y estrategias para su puesta en marcha","volume":"1","author":"Faus D\u00e1der MJ","year":"1999","journal-title":"Pharm Care Esp."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1590\/S0034-89102005000200007","article-title":"Blood glucose control in diabetes patients seen in primary health care centers","volume":"39","author":"Assun\u00e7\u00e3o MC","year":"2005","journal-title":"Rev Saude Publica."},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1900\/RDS.2006.3.82","article-title":"Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil","volume":"3","author":"Gomes MB","year":"2006","journal-title":"Rev Diabet Stud."},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","article-title":"Drug-related morbidity and mortality: updating the cost-of-illness model","volume":"41","author":"Ernst FR","year":"2001","journal-title":"J Am Pharm Assoc (Wash)."},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11096-006-9023-9","article-title":"Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma - interviewing patients at home","volume":"28","author":"Haugbolle LS","year":"2006","journal-title":"Pharm World Sci."},{"key":"ref15","series-title":"M\u00e9todo D\u00e1der: Gu\u00eda de Seguimento Farmacoterap\u00eautico","author":"Machuca M","year":"2003"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.29.s1.06.s4","article-title":"Standards of medical care in diabetes - 2006","volume":"29","year":"2006","journal-title":"Diabetes Care."},{"key":"ref17","series-title":"Conven\u00e7\u00e3o coletiva de trabalho 2006-2007","author":"Sindifar PR","year":"2006"},{"issue":"4","key":"ref18","first-page":"45","article-title":"Evaluaci\u00f3n econ\u00f3mica de la atenci\u00f3n farmac\u00e9utica (AF) en oficinas de farmacia comunitarias (Proyecto TOMCOR)","volume":"1","author":"Miragaya LC","year":"2002","journal-title":"Rev Esp Econ Salud."},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1524-4733.2003.64255.x","article-title":"Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program","volume":"6","author":"Etemad LR","year":"2003","journal-title":"Value Health."},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1516-31802002000400002","article-title":"Cost-effectiveness of hypertension treatment: a population-based study","volume":"120","author":"Dias da Costa JS","year":"2002","journal-title":"Sao Paulo Med J."},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1590\/S0034-89102005000300017","article-title":"An\u00e1lise econ\u00f4mica de programa para rastreamento do diabetes mellitus no Brasil","volume":"39","author":"Georg AE","year":"2005","journal-title":"Rev Sa\u00fade P\u00fablica."},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2337\/dc06-2070","article-title":"Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States","volume":"30","author":"Kim S","year":"2007","journal-title":"Diabetes Care."},{"key":"ref23","series-title":"DATASUS [Internet]: Informa\u00e7\u00f5es de sa\u00fade. Morbidade hospitalar","year":"2006"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1900\/RDS.2006.3.82","article-title":"Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multi-center study in Brazil","volume":"3","author":"Gomes MB","year":"2006","journal-title":"Rev Diab Stud."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18553\/jmcp.2006.12.2.130","article-title":"Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature","volume":"12","author":"Stephens JM","year":"2006","journal-title":"J Manag Care Pharm."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v53n7\/06.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T17:40:44Z","timestamp":1685209244000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302009000700006&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0004-27302009000700006"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302009000700006","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}